Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.